We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Clarifies Approach to Product-Specific Guidance Meetings for ANDAs
FDA Clarifies Approach to Product-Specific Guidance Meetings for ANDAs
The FDA has finalized advice for generic drug sponsors on seeking meetings with the agency to discuss the impact of a new or revised product-specific guidance (PSG) on their ANDA development programs.
